The stock price of Macrogenics Inc (NASDAQ: MGNX) has surged by 2.70 when compared to previous closing price of 13.31, but the company has seen a -3.87% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-07 that MacroGenics, Inc. (NASDAQ:MGNX ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Jim Karrels – Senior Vice President and Chief Financial Officer Scott Koenig – President and Chief Executive Officer Conference Call Participants Jonathan Chang – Leerink Partners Kelsey Goodwin – Guggenheim Stephen Willey – Stifel Etzer Darout – BMO Capital Markets Yigal Nochomovitz – Citigroup John Miller – Evercore Kaveri Pohlman – BTIG Tara Bancroft – TD Cowen Pete Lawson – Barclays Silvan Tuerkcan – Citizens JMP Operator Good afternoon. We will begin the MacroGenics 2023 Fourth Quarter Corporate Progress and Financial Results Conference Call in just a moment.
Is It Worth Investing in Macrogenics Inc (NASDAQ: MGNX) Right Now?
Additionally, the 36-month beta value for MGNX is 2.12. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for MGNX is 58.56M and currently, short sellers hold a 9.57% ratio of that float. The average trading volume of MGNX on April 04, 2024 was 1.41M shares.
MGNX’s Market Performance
The stock of Macrogenics Inc (MGNX) has seen a -3.87% decrease in the past week, with a -34.03% drop in the past month, and a 34.28% gain in the past quarter. The volatility ratio for the week is 6.46%, and the volatility levels for the past 30 days are at 7.54% for MGNX. The simple moving average for the last 20 days is -15.93% for MGNX stock, with a simple moving average of 55.35% for the last 200 days.
Analysts’ Opinion of MGNX
Many brokerage firms have already submitted their reports for MGNX stocks, with BTIG Research repeating the rating for MGNX by listing it as a “Buy.” The predicted price for MGNX in the upcoming period, according to BTIG Research is $24 based on the research report published on March 04, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MGNX reach a price target of $14, previously predicting the price at $12. The rating they have provided for MGNX stocks is “Neutral” according to the report published on February 14th, 2024.
Citigroup gave a rating of “Buy” to MGNX, setting the target price at $13 in the report published on December 20th of the previous year.
MGNX Trading at -15.89% from the 50-Day Moving Average
After a stumble in the market that brought MGNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.52% of loss for the given period.
Volatility was left at 7.54%, however, over the last 30 days, the volatility rate increased by 6.46%, as shares sank -33.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.88% upper at present.
During the last 5 trading sessions, MGNX fell by -3.87%, which changed the moving average for the period of 200-days by +127.45% in comparison to the 20-day moving average, which settled at $15.91. In addition, Macrogenics Inc saw 42.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MGNX starting from Peters Jeffrey Stuart, who sale 19,625 shares at the price of $21.50 back on Mar 06 ’24. After this action, Peters Jeffrey Stuart now owns 8,895 shares of Macrogenics Inc, valued at $421,938 using the latest closing price.
Risser Eric Blasius, the Chief Operating Officer of Macrogenics Inc, sale 41,159 shares at $19.76 during a trade that took place back on Mar 04 ’24, which means that Risser Eric Blasius is holding 38,900 shares at $813,501 based on the most recent closing price.
Stock Fundamentals for MGNX
Current profitability levels for the company are sitting at:
- -2.86 for the present operating margin
- 0.99 for the gross margin
The net margin for Macrogenics Inc stands at -0.15. The total capital return value is set at -0.69. Equity return is now at value -6.15, with -3.04 for asset returns.
Based on Macrogenics Inc (MGNX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.3. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 117.65.
Currently, EBITDA for the company is -168.24 million with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 13.29. The receivables turnover for the company is 5.67for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.48.
Conclusion
In conclusion, Macrogenics Inc (MGNX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
